Nuvation Bio Inc. (NUVB) NYSE
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Nuvation Bio Inc.
Address
1500 Broadway
New York City, NY 10036
United States of America (the)
Phone
332 208 6102
Website
Sector
Healthcare
Industry
Biotechnology
Employees
273
First IPO Date
August 26, 2020
Key Executives
| Name | Title | Pay | Year Born |
| David T. Hung | Founder, President, Chief Executive Officer & Chairman | 1.2M | 1958 |
| David C. Hanley | Chief Technical Operations Officer | 586,040 | 1970 |
| Colleen Sjogren | Chief Commercial Officer | 615,841 | 1971 |
| David Liu | Chief Medical Officer | 677,151 | 1970 |
| Gary Hattersley | Chief Scientific Officer | 805,803 | 1967 |
| Philippe Sauvage | Chief Financial Officer & Principal Financial Officer | 810,018 | 1978 |
| Kerry A. Wentworth | Chief Regulatory Officer | 0 | 1973 |
| Moses Makunje | Vice President of Finance and Principal Accounting & Financial Officer | 0 | 1979 |
| Robert DeVita | Vice President of Corporate Development & Investor Relations | 0 | N/A |
| Stacy Markel | Chief People Officer | 0 | 1965 |
| Stephen Dang | Chief Legal Officer & Corporate Secretary | 0 | N/A |
Description
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
